2-甲基-4-异吲哚啉胺 | 122993-59-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 中文名称: 2-甲基-4-异吲哚啉胺
• 中文别名: 2,3-二氢-2-甲基-1H-异吲哚-4-胺
• 英文名称: 4-amino-2,3-dihydro-2-methyl-1H-isoindole
• 英文别名: 2-methylisoindolin-4-amine；2,3-Dihydro-2-methyl-1H-isoindol-4-amine；2-methyl-1,3-dihydroisoindol-4-amine
• CAS: 122993-59-3
• 化学式: C₉H₁₂N₂
• mdl: MFCD10007250
• 分子量: 148.208
• InChiKey: MZQCHOUSVHXNFI-UHFFFAOYSA-N

物化性质

• 沸点：
  250.7±40.0 °C(Predicted)
• 密度：
  1.123±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-甲基-4-异吲哚啉胺 在 lithium aluminium tetrahydride 、 硫酸 、 sodium nitrite 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 4-Aminomethyl-2,3-dihydro-2-methyl-1H-isoindole
  参考文献：
  名称：

  Electron Impact Induced Loss of C-5/C-8 Substituents of 1,2,3,4-Tetrahydroisoquinolines, V: Synthesis and Mass Spectrometric Fragmentation of Dihydroisoindole Derivatives

  摘要：

  AbstractC‐8‐substituted N‐methyl‐1,2,3,4‐tetrahydroisoquinoline radical cations lose the complete substituent in a one step reaction giving rise to an unexpected ion at m/z 146, which is probably identical with the dihydroisoindolyl‐methyl‐cation A. The dihydroisoindoles 1, 10, and 16 were prepared as potentially alternative precursors of ion A. However, the ion at m/z 146 in their El mass spectra is of very low intensity, so CID‐experiments for structural comparison could not be performed. The electron impact induced fragmentations of 1, 10, and 16 are discussed.

  DOI：

  10.1002/ardp.19893220708
• 作为产物：
  描述：

  2-甲基-4-硝基异吲哚-1,3-二酮 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 2-甲基-4-异吲哚啉胺
  参考文献：
  名称：

  Electron Impact Induced Loss of C-5/C-8 Substituents of 1,2,3,4-Tetrahydroisoquinolines, V: Synthesis and Mass Spectrometric Fragmentation of Dihydroisoindole Derivatives

  摘要：

  AbstractC‐8‐substituted N‐methyl‐1,2,3,4‐tetrahydroisoquinoline radical cations lose the complete substituent in a one step reaction giving rise to an unexpected ion at m/z 146, which is probably identical with the dihydroisoindolyl‐methyl‐cation A. The dihydroisoindoles 1, 10, and 16 were prepared as potentially alternative precursors of ion A. However, the ion at m/z 146 in their El mass spectra is of very low intensity, so CID‐experiments for structural comparison could not be performed. The electron impact induced fragmentations of 1, 10, and 16 are discussed.

  DOI：

  10.1002/ardp.19893220708

文献信息

• NOVEL QUINOXALINEDIONE DERIVATIVES, THEIR PREPARATION AND USE
  申请人：——

  公开号：US20030114422A1

  公开（公告）日：2003-06-19

  A compound having the formula 1 or a pharmaceutically acceptable salt thereof wherein R is hydrogen or hydroxy; R 1 is hydrogen, alkyl, arylalkyl, (CH 2 ) n OH, or (CH 2 ) NR 7 R 8 ; R 5 and R 6 are each independently hydrogen, halogen, NO 2 , CN, CF 3 , SO 2 NR 7 R 8 , PO 3 R 9 R 10 , alkyl, alkenyl, alkynyl, (CH 2 ) n CONR 7 R 8 , (CH 2 ) n CO 2 R 10 , NHCOR 11 , wherein R 7 and R 8 are each independently hydrogen or alkyl or together R 7 and R 8 form a ring of from three to seven atoms, R 9 is hydrogen or alkyl, R 10 is hydrogen or alkyl, R 11 is hydrogen or alkyl, and n is an integer of from zero to four; A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b, and formed by the following bivalent radicals: a-NR 12 —CHR 13 —CHR 14 -b, a-CHR 13 —CHR 14 —NR 12 -b, a-CHR 13 —NR 12 —CHR 14 -b, a-CHR 14 —CH 2 —NR 12 —CHR 13 -b, a-CHR 13 —NR 12 —CH 2 —CHR 14 -b, a-CH 2 —CH 2 —CHR 13 —NR 12 -b, a-NR 12 —CHR 12 —CHR 13 —CH 2 —CH 2 -b, a-CH 2 —CH 2 —NR 12 —CH 2 —CH 2 -b, a-CH 2 —CH 2 —CH 2 NR 12 —CH 2 -b, a-CH 2 —NR 12 —CH 2 —CH 2 -b a-CH 2 —CH 2 —CH 2 —CH 2 —NR 12 -b, a-NR 12 —CH 2 —CH 2 —CH 2 —CH 2 -b, wherein R 12 is hydrogen, CH 2 CH 2 OH, or alkyl, and R 13 and R 14 are each independently hydrogen, CN, CONH 2 , CH 2 NH 2 , CH 2 OH, alkyl, arylalkyl, alkenyl, or CO 2 R 15 , wherein R 15 is hydrogen or alkyl. The compounds are useful in the treatment of disorders of mammals, responsive to the blockade of glutamic and aspartic acid receptors. Processes for preparing the compounds and novel intermediate useful in the processes are also included.

  具有以下式1的化合物或其药学上可接受的盐，其中R为氢或羟基；R1为氢、烷基、芳基烷基、(CH2)nOH或(CH2)NR7R8；R5和R6各自独立地为氢、卤素、NO2、CN、CF3、SO2NR7R8、PO3R9R10、烷基、烯基、炔基、(CH2)nCONR7R8、(CH2)nCO2R10、NHCOR11，其中R7和R8各自独立地为氢或烷基，或者一起形成由三至七个原子组成的环的R7和R8；R9为氢或烷基，R10为氢或烷基，R11为氢或烷基，n为从零到四的整数；A为与苯环在标记为a和b的位置融合的五至七个原子组成的环，并由以下二价基团形成：a-NR12—CHR13—CHR14-b，a-CHR13—CHR14—NR12-b，a-CHR13—NR12—CHR14-b，a-CHR14—CH2—NR12—CHR13-b，a-CHR13—NR12—CH2—CHR14-b，a-CH2—CH2—CHR13—NR12-b，a-NR12—CHR12—CHR13—CH2—CH2-b，a-CH2—CH2—NR12—CH2—CH2-b，a-CH2—CH2—CH2NR12—CH2-b，a-CH2—NR12—CH2—CH2-b，a-CH2—CH2—CH2—CH2—NR12-b，a-NR12—CH2—CH2—CH2—CH2-b，其中R12为氢、CH2CH2OH或烷基，R13和R14各自独立地为氢、CN、CONH2、CH2NH2、CH2OH、烷基、芳基烷基、烯基或CO2R15，其中R15为氢或烷基。这些化合物在治疗对谷氨酸和天冬氨酸受体阻滞有反应的哺乳动物的疾病中有用。还包括用于制备这些化合物的方法和在这些方法中有用的新中间体。
• Substituted isoquinoline derivatives and their use as anticonvulsants
  申请人：SmithKline Beecham p.l.c.

  公开号：US20010025045A1

  公开（公告）日：2001-09-27

  This invention relates to substituted isoquinoline derivatives and their use as anticonvulsants.

  这项发明涉及替代异喹啉衍生物及其作为抗癫痫药物的用途。
• Substituted benzamide derivatives and their use as anticonvulsants
  申请人：SmithKline Beecham p.l.c.

  公开号：US06110934A1

  公开（公告）日：2000-08-29

  This invention relates to substituted benzamido-heterocyclic compounds of general formula (I) having an alkoxy substituent at the C2 position of the benzamido group and various substituents at positions C4 and C5, being optionally substituted on the N atom of the heterocyclic system, and where the unsaturated ring of the heterocyclic system is a 5,6, 7 or 8-membered ring. Also to the use of these compounds as anticonvulsants in certain medical conditions, and to processes for making them.

  这项发明涉及一般式（I）的取代苯胺基-杂环化合物，其在苯胺基团的C2位置具有烷氧基取代基，在C4和C5位置具有各种取代基，可以在杂环系统的N原子上进行取代，并且杂环系统的不饱和环为5、6、7或8成员环。还涉及这些化合物作为抗惊厥剂在某些医疗状况中的使用，以及制备它们的方法。
• [EN] SUBSTITUTED BENZAMIDE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS<br/>[FR] DERIVES SUBSTITUES DU BENZAMIDE ET LEUR UTILISATION COMME ANTICONVULSIVANTS
  申请人：SMITHKLINE BEECHAM PLC

  公开号：WO1997048683A1

  公开（公告）日：1997-12-24

  (EN) The invention relates to substituted benzamido-heterocyclic compounds of general formula (I) having an alkoxy substituent at the C2 position of the benzamido group and various substituents at positions C4 and C5, being optionally substituted on the N atom of the heterocyclic system, and where the unsaturated ring of the heterocyclic system is a 5, 6, 7 or 8-membered ring. Also to the use of these compounds as anticonvulsants in certain medical conditions, and to processes for making them.(FR) L'invention concerne des composés benzamido-hétérocycliques substitués, de formule générale (I), comportant un substituant alcoxy en position C2 du groupe benzamido et divers substituants aux positions C4 et C5; éventuellement substitués sur l'atome N du système hétérocyclique; et dans lesquels le noyau insaturé du système hétérocyclique est un noyau à 5, 6, 7 ou 8 éléments. L'invention concerne également l'utilisation de ces composés comme anticonvulsivants dans certains troubles médicaux, ainsi que les procédés permettant de les fabriquer.

  本发明涉及一般式（I）的取代苯甲酰胺-杂环化合物，其在苯甲酰胺基团的C2位置具有烷氧基取代基，在C4和C5位置具有各种取代基，可以在杂环系统的N原子上选用取代基，且杂环系统的不饱和环为5、6、7或8元环。此外，本发明还涉及将这些化合物用作某些医疗条件下的抗惊厥药物，以及制备它们的过程。
• Quinoxalinedione derivatives, their preparation and use
  申请人：Neurosearch A/S

  公开号：US06703391B2

  公开（公告）日：2004-03-09

  A compound having the formula or a pharmaceutically acceptable salt thereof wherein R is hydrogen or hydroxy; R1 is hydrogen, alkyl, arylalkyl, (CH2)nOH, or (CH2)nNR7R8; R5 and R6 are each independently hydrogen, halogen, NO2, CN, CF3, SO2NR7R8, PO3R9R10, alkyl, alkenyl, alkynyl, (CH2)nCONR7R8, (CH2)nCO2R10, NHCOR11, A is a ring formed by the following: a-NR12—CHR13—CHR14-b, a-CHR13—CHR14—NR12-b, a-CHR13—NR12—CHR14-b, a-CHR14—CH2—NR12—CHR13-b, a-CHR13—NR12—CH2—CHR14-b, a-CH2—CH2—CHR13—NR12-b, a-NR12—CHR13—CHR12—CH2—CH2-b, a-CH2—CH2—NR12—CH2—CH2-b, a-CH2—CH2—CH2NR12—CH2-b, a-CH2—NR12—CH2—CH2-b a-CH2—CH2—CH2—CH2—NR12-b, a-NR12—CH2—CH2—CH2—CH2-b, The compounds are useful in the treatment of disorders responsive to the blockade of glutamic and aspartic acid receptors.

  一种具有以下化学式或其药学上可接受的盐的化合物，其中：R为氢或羟基；R1为氢、烷基、芳基烷基、(CH2)nOH或(CH2)nNR7R8；R5和R6各自独立地为氢、卤素、NO2、CN、CF3、SO2NR7R8、PO3R9R10、烷基、烯基、炔基、(CH2)nCONR7R8、(CH2)nCO2R10、NHCOR11；A为以下环：a-NR12—CHR13—CHR14-b、a-CHR13—CHR14—NR12-b、a-CHR13—NR12—CHR14-b、a-CHR14—CH2—NR12—CHR13-b、a-CHR13—NR12—CH2—CHR14-b、a-CH2—CH2—CHR13—NR12-b、a-NR12—CHR13—CHR12—CH2—CH2-b、a-CH2—CH2—NR12—CH2—CH2-b、a-CH2—CH2—CH2NR12—CH2-b、a-CH2—NR12—CH2—CH2-b、a-CH2—CH2—CH2—CH2—NR12-b、a-NR12—CH2—CH2—CH2—CH2-b。这些化合物可用于治疗对谷氨酸和天冬氨酸受体阻滞有反应的疾病。